Ribon Therapeutics

Ribon Therapeutics is a privately held biotechnology company headquartered in Cambridge, Massachusetts, in the United States. The company is focused on the discovery and development of small-molecule therapeutics that target mono-ADP ribosyltransferases (mono-ARTs) and related enzyme families involved in cellular stress responses, DNA damage repair, and immune signaling. Its research is positioned at the intersection of cancer biology and inflammation, with the goal of delivering first-in-class or best-in-class oral agents for oncology and immuno-oncology indications. Ribon Therapeutics operates as a research-stage biopharmaceutical company. Its pipeline has historically centered on inhibitors of mono-ART enzymes such as tankyrase and other PARP-family proteins, with lead programs directed at solid tumors and hematologic malignancies. The company has been backed by private venture capital and institutional investors, and it has pursued collaborations and licensing arrangements to advance its preclinical and clinical candidates. The company is part of the dense life-sciences cluster in Cambridge, Massachusetts, one of the world's leading hubs for biotechnology research and drug development. As a private company, Ribon Therapeutics does not disclose detailed financial results publicly, and its ownership structure is not widely reported. Its corporate identity is that of a clinical-stage oncology-focused biotech rather than a commercial-stage pharmaceutical manufacturer.

Ribon Therapeutics was established as a biotechnology company based in Cambridge, Massachusetts, United States. The company was founded to pursue a specific scientific thesis: that mono-ADP ribosyltransferases (mono-ARTs), a family of enzymes that attach single ADP-ribose units to target proteins, represent a tractable and largely untapped class of drug targets for cancer and other diseases. This focus distinguished Ribon from the many biotechs working on more heavily pursued kinase or immuno-oncology pathways. From its early years, Ribon Therapeutics built a discovery platform around small-molecule inhibitors of mono-ART enzymes. Its research efforts have included programs directed at tankyrase, a mono-ART involved in Wnt signaling and telomere maintenance, as well as other PARP-family enzymes implicated in DNA damage response and cellular stress. The company's stated aim has been to develop oral, selective inhibitors that could be used as single agents or in combination with existing cancer therapies. As a private, venture-backed company, Ribon Therapeutics has financed its operations through private investment rounds rather than public markets. It has operated within the Cambridge, Massachusetts life-sciences ecosystem, which provides access to academic research institutions, contract research organizations, and a deep pool of scientific talent. The company has pursued a clinical-stage strategy, advancing selected candidates from discovery into early-phase human trials while maintaining a broader preclinical pipeline. Specific details of Ribon Therapeutics' founding year, founders, financing history, and clinical milestones are not fully captured in the available public evidence. The company remains active as of the latest available information, with its headquarters in Cambridge, Massachusetts, and its research focused on mono-ART-targeted therapeutics.

Clinical-stage oncology biotechnology company focused on mono-ADP ribosyltransferase (mono-ART) targeted small-molecule therapeutics.

Product categories. Small-molecule mono-ART inhibitors · Oncology drug candidates

1. 1Ribon Therapeutics (United States) - Wikidatawikidata.org
2. 2Ribon Therapeutics official websiteribontx.com